Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.70 |
| ▸ | BACE2 | Q9Y5Z0 | 16/20 | 0.70 |
| ▸ | CTSD | P07339 | 4/20 | 0.62 |
| ▸ | CTSE | P14091 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7612190 | 1.00 | BACE1 (0.70) | BACE1BACE2CTSDCTSE | |
| SCHEMBL4889542 | 0.93 | BACE1 (0.75) | BACE1BACE2CTSDCTSE | |
| SCHEMBL7607871 | 0.93 | BACE1 (0.75) | BACE1BACE2CTSDCTSE | |
| SCHEMBL4888823 | 0.89 | BACE1 (0.67) | BACE1BACE2CTSD | |
| SCHEMBL7603970 | 0.89 | BACE1 (0.67) | BACE1BACE2CTSD | |
| SCHEMBL4887067 | 0.88 | BACE1 (0.68) | BACE1BACE2CTSDCTSE | |
| SCHEMBL4889675 | 0.88 | BACE1 (0.83) | BACE1BACE2CTSD | |
| SCHEMBL7603961 | 0.88 | BACE1 (0.83) | BACE1BACE2CTSD | |
| SCHEMBL4882318 | 0.87 | BACE1 (0.69) | BACE1BACE2CTSD | |
| SCHEMBL3351088 | 0.87 | BACE1 (0.84) | BACE1BACE2CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | claimed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | claimed |
| US-20020019403-A1 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-14 | — | — | US | claimed |
| US-20080058336-A1 | Methods to Treat Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | disclosed |
| EP-1265849-B1 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-7119085-B2 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-7030239-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-6992081-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| US-6737420-B2 | A SUBSTITUTED HYDROXYETHYLENE COMPOUND USEFUL FOR TREATING ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, DOWN'S SYNDROME, HEREDIATARY CEREBRAL HEMMORRHAGE WITH AMYLOIDOSIS, DEGENERATIVE DEMENTIA | ELAN PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | disclosed |
| US-20020019403-A1 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | PSEN1, PSEN2, BACE1 | BACE1 3/4885BACE2 8/4885CTSD 1953/4885 |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BCHE | BACE1 5/4885BACE2 8/4885CTSD 1453/4885 |
| US-20020019403-A1 | Methods to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | BACE1 3/4885BACE2 9/4885CTSD 2159/4885 |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | BACE1 5/4885BACE2 9/4885CTSD 1945/4885 |
| US-20080058336-A1 | Methods to Treat Alzheimer's Disease | PSEN2, PSEN1, ACHE | BACE1 9/4885BACE2 8/4885CTSD 1469/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | BACE1 3/4885BACE2 8/4885CTSD 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.